Material and methods A retrospective observational study was conducted in a diabetic clinic of a regional hospital. Clinical data and demographic characteristics were obtained from computerised medical records and processed by Microsoft Excel. Overall, 52 participants were selected with T2DM who were treated with IDegLira in addition to oral antidiabetic drugs for at least 52 weeks between October 2016 and January 2018. The effectiveness of IDegLira was analysed through measuring glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), and bodyweight and lipid profile parameters at the beginning of the treatment and at week 52.

Results Fifty-two patients were included in total. Mean age: 61.2 years (38–78); 25 females and 27 males. Average duration of diabetes: 8.5 years (2.8–19.9). After 52 weeks the mean HbA1c decreased from a baseline of 72.3 ± 1.4 mmol/mol by 7.3 ± 1.8 mmol/mol ($p < 0.001$). The mean FPG was reduced from a baseline of 9.6 ± 0.4 mmol/L by 1.5 ± 0.4 mmol/L ($p < 0.001$). Average weight loss was -0.45 ± 0.32 kg ($p = 0.161$). Mean changes in lipid profile parameters such as total cholesterol, LDL-cholesterol and triglycerides were statistically insignificant except for HDL-cholesterol, which increased from a baseline of 1.06 ± 0.05 mmol/L by 0.04 ± 0.02 mmol/L ($p = 0.014$). Compared to the data from the DUAL Clinical Trial Programme, the reduction in glycemic parameters attained in this study was less pronounced presumably due to the smaller number of participants and different baseline characteristics.

Conclusion The conducted study confirms that the positive impact of IDegLira on glycemic compensation in patients with T2DM as a statistically significant decrease in parameters of glycemic control was achieved. On the contrary, the weight reduction and almost all the changes in plasma lipid concentrations were insignificant.

REFERENCES AND/OR ACKNOWLEDGEMENTS

<https://onlinelibrary.wiley.com/doi/full/10.1111/dom.12498>

No conflict of interest.

6ER-003 COST OF VENOUS THROMBOEMBOLIC DISEASE IN PATIENTS WITH LUNG AND PROSTATE CANCER: COSTECAT STUDY

¹R Ana Rosa*, ²MA Calleja, ³MD Alvarado, ⁴F Artime, ⁵B Bernardez, ⁶V Escudero, ⁷C García, ⁸I Mangués, ⁹JA Marcos. ¹Hospital Virgen de La Salud, Pharmacy, Toledo, Spain; ²Hospital Universitario Virgen Macarena, Pharmacy, Sevilla, Spain; ³Hospital Universitario Virgen de Las Nieves, Pharmacy, Granada, Spain; ⁴Hospital Universitari Arnau de Vilanova, Pharmacy, Lleida, Spain; ⁵Complejo Hospitalario Universitario de Santiago, Pharmacy, Santiago de Compostela, Spain; ⁶Hospital General Universitario Gregorio Marañón, Pharmacy, Madrid, Spain

10.1136/ejhp-pharm-2019-eahpconf.601

Background Patients with cancer are at significantly higher risk of developing, and dying from, venous thromboembolism (VTE). The CLOT and CATCH trials demonstrated the superiority of low-molecular-weight heparins (LMWH) over warfarin for recurrent VTE and established LMWH as the standard of care for cancer-associated VTE.

Purpose The aim of the present study was to determine the number of admissions and the cost of the management of VTE events occurring in patients with lung cancer (LC) or prostate cancer (PC).

Material and methods This was a multicentre, observational, ambispective pharmaco-economic study involving six third-level hospitals. Patients with LC or PC who had suffered a first

episode or a recurrent symptomatic or incidental VTE recurrence and who were receiving treatment with LMWH were included.

The data was collected through medical records and/or the discharge reports, as well as the information provided by the patient during the study visit as well as the information the patient collected in their patient diary during the follow-up period.

All hospitalisations and ambulatory cost related to VTE (primary diagnosis or related diagnosis) were recorded. Anticancer therapy was not collected. Costs were estimated through the consumption of resources collected in the eCRF and derivatives of the information from the patient's diaries associated with the handling of the episode of VTE.

Results Fifty-five patients were included from October 2017 to April 2018. The last patient visit was recorded in October 2018. The results will be presented during the EAHP 2019.

Conclusion Among the solid tumours with higher absolute risk of VTE are PC and LC that in our country represented the second and third most prevalent cancer according to the GLOBOCAN 2012 report.

VTE represents a great economic burden on health systems and society, mainly due to the treatment of initial and recurrent events that require hospitalisation.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

6ER-005 USE OF SACUBITRIL/VALSARTAN IN PATIENTS WITH CHRONIC HEART FAILURE

¹L Enríquez Olivar*, ²AM López González, ²S Izquierdo Muñoz, ²E Queipo García, ²MT Sánchez Sánchez. ¹Hospital Clínico Universitario, Hospital Pharmacy, Valladolid, Spain; ²Hospital Clínico Universitario de Valladolid, Hospital Pharmacy, Valladolid, Spain

10.1136/ejhp-pharm-2019-eahpconf.602

Background Recommendations approved by the local Pharmacy and Therapeutics Committee (PTC) for the prescription of Sacubitril/Valsartan (SV) are: patients with chronic symptomatic heart failure (HF) (II–III grade following New York Association (NYHA)) with reduced left ejection fraction (LVEF <35%) and elevated N-terminal Pro B-type natriuretic peptide (NT-proBNP >640 pg/ml) seric levels to be treated with standard of care therapy: angiotensin converting enzyme inhibitors (ACE) or angiotensin II receptor blockers (ARB), in combination with beta-blockers (BB) and mineralcorticoid antagonists.

Purpose To evaluate the adherence to the recommendations of the PTC concerning the prescriptions of SV on hospital admission.

Material and methods A descriptive, observational and prospective study including patients treated with SV from March 2018 to July 2018 in a General Teaching Hospital.

Variables considered were: sex, age, patient chronic and fragile (G3), according to the stratification of the regional Health Service, HF NYHA classification, LVEF, NT-proBNP, previous treatment with ACE inhibitors/ARBs, BB and mineralcorticoid antagonists at hospital admission and glomerular filtration rate (GFR).

Results Fifty-one patients were included: 84% (43/51) were men, average 69 ± 11 years and 51% (30/51) were G3.